Genmab A/S operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Genmab A/S with three other
miscellaneous service companies in Europe:
Bachem Holding AG
sales of 261.61 million Swiss Francs [US$259.28 million]
of which 88%
was Active Pharmaceutical Ingredients),
Clinigen Group PLC
of the United Kingdom
(£302.30 million [US$388.56 million]
of which 36%
was Clinical Trial services), and
based in Sweden
(2.33 billion Swedish Kronor [US$251.74 million]
of which 60%
Genmab A/S reported sales of 2.37 billion Danish Kroner (US$356.99 million)
December of 2017.
increase of 30.2%
versus 2016, when the company's sales were 1.82 billion Danish Kroner.
Sales at Genmab A/S have increased during each of the previous five years
(and since 2012, sales have increased a total of 388%).